CFRD patients generally have more rapid gastric emptying and lower gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) (which prime and stimulate insulin release) levels than CF and control groups (53, 54). The gene discussed is GCG; the disease is cystic fibrosis-related diabetes.